(Q30367176)

21 June 2017

1 reference

title

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. (English)

1 reference

21 June 2017

1 reference

Joseph Sodroski

1 reference

21 June 2017

Ron A M Fouchier

1 reference

21 June 2017

Dennis R Burton

1 reference

21 June 2017

Richard T Wyatt

1 reference

21 June 2017

author name string

Gunilla B Karlsson Hedestam

series ordinal

1 reference

21 June 2017

Sanjay Phogat

series ordinal

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Nature Reviews Microbiology

21 June 2017

published in

1 reference

21 June 2017

1 reference

21 June 2017

1 reference

21 June 2017

page(s)

143-155

1 reference

Making better influenza virus vaccines?

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Role of neutralizing antibodies in protective immunity against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Immunologic correlates of protection induced by vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Scientific barriers to developing vaccines against avian influenza viruses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Avian influenza A (H5N1) in 10 patients in Vietnam

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

The rational design of an AIDS vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

HIV vaccine design and the neutralizing antibody problem

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Viral persistence: HIV's strategies of immune system evasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Mapping the antigenic and genetic evolution of influenza virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Antibody neutralization and escape by HIV-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Neutralizing antibodies and the course of HIV-induced disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Antibody vs. HIV in a clash of evolutionary titans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Binding of the influenza A virus to cell-surface receptors: structures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

The structure and function of the hemagglutinin membrane glycoprotein of influenza virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structural basis of immune recognition of influenza virus hemagglutinin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

N-linked glycosylation attenuates H3N2 influenza viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

An antibody that prevents the hemagglutinin low pH fusogenic transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure of influenza virus haemagglutinin complexed with a neutralizing antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure of an unliganded simian immunodeficiency virus gp120 core

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

31 March 2020

V3: HIV's switch-hitter

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure of a V3-containing HIV-1 gp120 core

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Mechanism of neutralization of influenza virus infectivity by antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Intranasal, cold-adapted, live, attenuated influenza vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Development of effective vaccines against pandemic influenza.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Influenza and the challenge for immunology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Combination DNA plus protein HIV vaccines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

GP120: target for neutralizing HIV-1 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Exploiting the defensive sugars of HIV-1 for drug and vaccine design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structural definition of a conserved neutralization epitope on HIV-1 gp120

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Energetics of the HIV gp120-CD4 binding reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Comparing antigenicity and immunogenicity of engineered gp120.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

The antigenic structure of the HIV gp120 envelope glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Mannose receptor-mediated regulation of serum glycoprotein homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Adjuvants for human vaccines--current status, problems and future prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Survey of human-use adjuvants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

CpG oligodeoxynucleotides as vaccine adjuvants in primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Silent mutation pattern in V3 sequences distinguishes virus according to risk group in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Further Studies on the Activation of Influenza Virus by Proteolytic Cleavage of the Haemagglutinin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Activation of influenza A viruses by trypsin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Glycoconjugate glycans as viral receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Receptor binding properties of human and animal H1 influenza virus isolates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Virus-like particles as HIV-1 vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Distribution and three-dimensional structure of AIDS virus envelope spikes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Influenza virus pleiomorphy characterized by cryoelectron tomography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

Change in tropism upon immune escape by human immunodeficiency virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

7 January 2021

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

7 January 2021

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

7 January 2021

A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO1819

7 January 2021

Identifiers

DOI

10.1038/NRMICRO1819

1 reference

Dimensions Publication ID

21 June 2017

1031201834

0 references

1 reference